Dr. Sandip Ganguly

He has published over 123 articles. Some of them are:

• Real-world study of safety and efficacy of erlotinib as second line and beyond in ALK-rearranged advanced non-small cell lung cancer patients in India – a multicentre chart review study (ROSELAND)
• Real-world survival outcomes and treatment patterns in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the OREIOS study.
• Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
• LBA11 Amivantamab plus chemotherapy vs. chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis
• 287MO Real-world experience with maintenance PARP inhibitor plus minus bevacizumab in newly diagnosed advanced ovarian cancer with germline BRCA mutations or homologous recombination deficiency (HRD) positive
• Amivantamab plus chemotherapy with and without lapatinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
• 272P Correlation of dihydropyrimidine dehydrogenase gene mutation with toxicity among gastrointestinal cancers (GI) taking 5-fluorouracil-based chemotherapy: Experience from a tertiary cancer center in the eastern part of India
• 272P Correlation of dihydropyrimidine dehydrogenase gene mutation with toxicity among gastrointestinal cancers (GI) taking 5-fluorouracil-based chemotherapy: Experience from a tertiary cancer center in the eastern part of India
• Pancreatic Adenocarcinoma with Primary Tumor Calcification and Calcified Liver Metastasis: Report of a Rare Case and Review of Literature
• Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over three weeks) with a novel 1-week schedule in adjuvant breast cancer: An open-label randomized controlled study (HYPORT-Adjuvant) - Study protocol for a multicentre, randomized phase III trial